Improved Oral Health in Adults With X-Linked Hypophosphatemia Treated With Burosumab
Authors' conclusion
We observed that adults with XLH treated with burosumab developed fewer endodontic infections during dental follow-up than patients who were untreated or received CT.
Study context
- Population
- Adults with X-linked hypophosphatemia (XLH) who had undergone dental monitoring for at least 6 months
- Participants
- 44 adults
- Exposure
- Burosumab vs conventional treatment vs no treatment
- Outcome
- Oral health (number of missing or endodontically treated teeth, periodontal disease) and incidence of endodontic infections
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Incidence of dental infections during follow-up
Reduction of infections
55.9%
P < 0.0001
Conventional treatment (CT)
Reduction of infections
86.4%
P < 0.0001
Burosumab
Observational data: associations, not effects.
Further findings
Infection incidence, within-patient comparison of treatment vs nontreatment periods
- Strong association between burosumab treatment and decreased infection incidence (infection per month)
- .006 vs .09, P < .01
Original publication
Improved Oral Health in Adults With X-Linked Hypophosphatemia Treated With Burosumab. J Clin Endocrinol Metab. Published 12 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →